Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-06-14
Intellia Therapeutics, Inc.
Intellia develops in vivo CRISPR gene-editing therapies for hereditary angioedema, transthyretin amyloidosis, and selected partnered liver-directed diseases.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First In-Vivo CRISPR Revenue Is Finally Visible
The story is shifting from abstract platform optionality toward a tangible rare-disease launch. A successful HAE commercialization could create a real franchise, but the second act still depends on rebuilding confidence in ATTR and avoiding another regulatory reset.

Analysis

Thesis
If lonvo-z converts Phase 3 proof into approval, payer access, and a credible 2027 launch, Intellia can rerate from cash-burning platform story to a real rare-disease franchise; the 2031 upside is driven mainly by HAE commercialization, partial ATTR recovery, and capital-light partnering rather than full blue-sky platform value.
Last Economy Alignment
AI should make discovery, trial operations, and manufacturing learning cheaper, and Intellia owns valuable edit, safety, and regulatory know-how. But the real bottlenecks are still biology, FDA permissioning, manufacturing quality, and payer and physician trust.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 4 most recent analyses)
Reasoning
The upside is a change in what investors think they own: not just a research platform, but a company with a launched one-time therapy, reusable rare-disease commercial infrastructure, and a second franchise that still has real option value. I do not underwrite a full platform moonshot; the case is mostly lonvo-z plus partial credit for nex-z and smarter partnering.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This thesis is now mostly conversion risk, not pure science risk. Intellia must turn strong HAE data into a completed filing, approval, payer access, site readiness, and durable physician trust while rebuilding confidence in ATTR after the prior hold. If lonvo-z launches slowly or nex-z stays constrained, the stock can remain a one-asset, dilution-sensitive story.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.33
They control hard-to-copy gene-editing know-how, human safety data, and a real path to a one-time medicine, so better AI should help them design and operate faster. But AI cannot remove the true bottlenecks here: biology, FDA review, manufacturing quality, and doctor and payer trust.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$26.63
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case